Alkermes Plc (ALKS) SVP Michael J. Landine Sells 25,000 Shares

Alkermes Plc (NASDAQ:ALKS) SVP Michael J. Landine sold 25,000 shares of Alkermes stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $33.05, for a total transaction of $826,250.00. Following the transaction, the senior vice president now owns 210,122 shares of the company’s stock, valued at $6,944,532.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of ALKS traded up $0.85 on Friday, hitting $34.02. 43,772 shares of the stock traded hands, compared to its average volume of 830,443. The company has a market capitalization of $5.19 billion, a P/E ratio of -486.00 and a beta of 1.82. The company has a quick ratio of 2.63, a current ratio of 2.89 and a debt-to-equity ratio of 0.24. Alkermes Plc has a one year low of $27.54 and a one year high of $62.42.

Alkermes (NASDAQ:ALKS) last announced its quarterly earnings results on Thursday, February 14th. The company reported $0.34 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.39. The company had revenue of $316.00 million during the quarter, compared to the consensus estimate of $255.71 million. Alkermes had a negative net margin of 12.73% and a negative return on equity of 0.49%. The firm’s quarterly revenue was up 14.9% compared to the same quarter last year. During the same quarter last year, the firm earned $0.31 earnings per share. On average, sell-side analysts expect that Alkermes Plc will post -0.41 EPS for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in ALKS. Norges Bank bought a new stake in shares of Alkermes during the fourth quarter valued at approximately $31,645,000. Pictet Asset Management Ltd. bought a new stake in shares of Alkermes during the third quarter valued at approximately $20,626,000. Two Sigma Investments LP grew its position in Alkermes by 377.1% in the 4th quarter. Two Sigma Investments LP now owns 479,458 shares of the company’s stock worth $14,149,000 after purchasing an additional 378,964 shares during the period. Canada Pension Plan Investment Board grew its position in Alkermes by 62.4% in the 4th quarter. Canada Pension Plan Investment Board now owns 776,050 shares of the company’s stock worth $22,899,000 after purchasing an additional 298,289 shares during the period. Finally, First Manhattan Co. grew its position in Alkermes by 50.9% in the 4th quarter. First Manhattan Co. now owns 838,894 shares of the company’s stock worth $24,755,000 after purchasing an additional 282,900 shares during the period. 97.83% of the stock is owned by institutional investors.

Several equities analysts have recently issued reports on ALKS shares. Zacks Investment Research upgraded shares of Alkermes from a “hold” rating to a “buy” rating and set a $36.00 target price for the company in a report on Tuesday, January 29th. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Alkermes in a report on Thursday, January 10th. ValuEngine lowered shares of Alkermes from a “hold” rating to a “sell” rating in a report on Wednesday, January 2nd. Goldman Sachs Group lowered shares of Alkermes from a “neutral” rating to a “sell” rating and lowered their target price for the company from $49.00 to $26.00 in a report on Tuesday, December 18th. Finally, BidaskClub upgraded shares of Alkermes from a “hold” rating to a “buy” rating in a report on Saturday, January 12th. Four investment analysts have rated the stock with a sell rating, six have assigned a hold rating and six have issued a buy rating to the company’s stock. Alkermes has a consensus rating of “Hold” and a consensus target price of $44.15.

TRADEMARK VIOLATION NOTICE: This piece of content was published by WKRB News and is owned by of WKRB News. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.wkrb13.com/2019/03/15/alkermes-plc-alks-svp-michael-j-landine-sells-25000-shares.html.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability.

See Also: Ex-Dividend

Insider Buying and Selling by Quarter for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply